Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SER Stock Forecast 2026-2027
$2.10
Current Price
$25.86M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SER Price Targets
+423.8%
To High Target of $11.00
+423.8%
To Median Target of $11.00
+423.8%
To Low Target of $11.00
SER Price Momentum
+3.4%
1 Week Change
-17.3%
1 Month Change
-61.8%
1 Year Change
+9.9%
Year-to-Date Change
-73.5%
From 52W High of $7.92
+72.1%
From 52W Low of $1.22
📊 TOP ANALYST CALLS
Did SER Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Serina Therapeutics is one of their latest high-conviction picks.
Latest SER Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, SER has a bullish consensus with a median price target of $11.00 (ranging from $11.00 to $11.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $2.10, the median forecast implies a 423.8% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SER Analyst Ratings
1
Buy
0
Hold
0
Sell
SER Price Target Range
Low
$11.00
Average
$11.00
High
$11.00
Current: $2.10
Latest SER Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SER.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 28, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 14, 2025 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Mar 11, 2025 | Jones Trading | Buy | Initiates | $N/A |
Serina Therapeutics Inc. (SER) Competitors
The following stocks are similar to Serina Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Serina Therapeutics Inc. (SER) Financial Data
Serina Therapeutics Inc. has a market capitalization of $25.86M with a P/E ratio of 1.6x. The company generates $130,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -18,478.5% and return on equity of -8,159.2%.
Valuation Metrics
Market Cap
$25.86M
Enterprise Value
$31.07M
P/E Ratio
1.6x
PEG Ratio
-2.0x
Price/Sales
198.9x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-18,478.5%
Net Margin
0.0%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+11.8%
Current Ratio
1.7x
Debt/Equity
-89.8x
ROE
-8,159.2%
ROA
-219.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Serina Therapeutics Inc. (SER) Business Model
About Serina Therapeutics Inc.
What They Do
Develops polymer-based therapeutics for medical challenges.
Business Model
The company leverages its proprietary polyoxazoline (POZ) polymer technology to enhance the delivery and efficacy of pharmaceuticals. By improving pharmacokinetics and safety profiles of drug candidates, it generates revenue through partnerships, licensing agreements, and potential commercialization of its innovative therapeutics targeting neurological diseases, cancer, and autoimmune conditions.
Additional Information
Serina Therapeutics is positioned within the competitive biotechnology and pharmaceutical sectors, focusing on unmet medical needs and the evolving demands of precision medicine. Its POZ technology represents a significant advancement in drug delivery, with potential to reduce side effects and prolong therapeutic effects.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
12
CEO
Mr. Steven A. Ledger
Country
United States
IPO Year
2024
Website
serinatherapeutics.comSerina Therapeutics Inc. (SER) Latest News & Analysis
Latest News
Quick Summary
Serina Therapeutics (NYSE: SER) announced advancements in its POZ Platform™ at a summit, showing novel lipid nanoparticles that avoid PEG immunogenicity, with successful test results in rats.
Why It Matters
Serina's breakthrough in overcoming PEG immunogenicity with its POZ Platform could enhance drug delivery systems, potentially leading to more effective therapies and increasing investor confidence in its pipeline.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
19 days ago
Quick Summary
Serina Therapeutics, Inc. (NYSE American: SER) is working to regain compliance with NYSE American listing standards, having had its business plan accepted by the exchange.
Why It Matters
Serina Therapeutics’ acceptance of a compliance plan indicates potential stabilization and future growth, which may boost investor confidence and affect stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Serina Therapeutics, Inc. (NYSE American: SER) CEO Steve Ledger will present at the 38th Annual Roth Conference in Dana Point, CA on March 24, 2026, at 11:30 a.m. PST.
Why It Matters
Steve Ledger's presentation at a prominent conference may signal potential advancements or partnerships for Serina, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A $15 million stock sale tranche is set to close on March 20, 2026, with a potential second tranche bringing total proceeds to $30 million. Shares priced at $2.25, a 68% premium to March 17 close.
Why It Matters
The planned capital raise at a significant premium indicates investor confidence, potentially boosting stock value and liquidity while providing funds for growth initiatives.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The Safety Monitoring Committee will evaluate safety and tolerability data from Cohort 1, with advancements to Cohort 2 anticipated in Q3 2026.
Why It Matters
The timeline for safety evaluations and progression to Cohort 2 signals critical milestones for the clinical trial, potentially affecting stock valuations and investor confidence in the company’s prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Serina has enrolled its first patient in a global study in Australia, aiming for first patient dosing in Cohort 1 by Q1 2026.
Why It Matters
Successful enrollment in a global study indicates progress for Serina, potentially boosting investor confidence and stock value as they approach significant milestones in drug development.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SER Stock
What is Serina Therapeutics Inc.'s (SER) stock forecast for 2026?
Based on our analysis of 1 Wall Street analysts, Serina Therapeutics Inc. (SER) has a median price target of $11.00. The highest price target is $11.00 and the lowest is $11.00.
Is SER stock a good investment in 2026?
According to current analyst ratings, SER has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $2.10. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SER stock?
Wall Street analysts predict SER stock could reach $11.00 in the next 12 months. This represents a 423.8% increase from the current price of $2.10. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Serina Therapeutics Inc.'s business model?
The company leverages its proprietary polyoxazoline (POZ) polymer technology to enhance the delivery and efficacy of pharmaceuticals. By improving pharmacokinetics and safety profiles of drug candidates, it generates revenue through partnerships, licensing agreements, and potential commercialization of its innovative therapeutics targeting neurological diseases, cancer, and autoimmune conditions.
What is the highest forecasted price for SER Serina Therapeutics Inc.?
The highest price target for SER is $11.00 from at , which represents a 423.8% increase from the current price of $2.10.
What is the lowest forecasted price for SER Serina Therapeutics Inc.?
The lowest price target for SER is $11.00 from at , which represents a 423.8% increase from the current price of $2.10.
What is the overall SER consensus from analysts for Serina Therapeutics Inc.?
The overall analyst consensus for SER is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $11.00.
How accurate are SER stock price projections?
Stock price projections, including those for Serina Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 21, 2026 10:37 AM UTC